Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 11916914
Lingohr MK, et al. (2002) Activation of IRS-2-mediated signal transduction by IGF-1, but not TGF-alpha or EGF, augments pancreatic beta-cell proliferation. Diabetes 51, 966-76 11916914
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T308-p - Akt1 (rat)
Modsite: KDGATMKtFCGTPEy SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): T308‑p, Akt1 iso2 (human): T246‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  INS-1 (pancreatic)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
glucose increase
IGF-1 glucose augment treatment-induced increase sustained increase
EGF glucose augment treatment-induced increase transient increase
TGF-alpha glucose augment treatment-induced increase transient increase

S473-p - Akt1 (rat)
Modsite: RPHFPQFsYSASGTA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  INS-1 (pancreatic)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
glucose increase
IGF-1 glucose augment treatment-induced increase sustained increase
EGF glucose augment treatment-induced increase transient increase
TGF-alpha glucose augment treatment-induced increase transient increase

T203-p - ERK1 (rat)
Modsite: HDHTGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  INS-1 (pancreatic)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
glucose increase
IGF-1 glucose augment treatment-induced increase
TGF-alpha no effect upon treatment-induced increase
EGF no effect upon treatment-induced increase

Y205-p - ERK1 (rat)
Modsite: HTGFLtEyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  INS-1 (pancreatic)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
glucose increase
IGF-1 glucose augment treatment-induced increase
TGF-alpha no effect upon treatment-induced increase
EGF no effect upon treatment-induced increase

T183-p - ERK2 (rat)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  INS-1 (pancreatic)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
glucose increase
IGF-1 glucose augment treatment-induced increase
TGF-alpha no effect upon treatment-induced increase
EGF no effect upon treatment-induced increase

Y185-p - ERK2 (rat)
Modsite: HtGFLtEyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  INS-1 (pancreatic)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
glucose increase
IGF-1 glucose augment treatment-induced increase
TGF-alpha no effect upon treatment-induced increase
EGF no effect upon treatment-induced increase

T19-p - GSK3A (rat)
Modsite: GGSGRARtssFAEPG SwissProt Entrez-Gene
Orthologous residues
GSK3A (human): T19‑p, GSK3A (mouse): T19‑p, GSK3A (rat): T19‑p, GSK3A (cow): T19‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  INS-1 (pancreatic)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
glucose increase
IGF-1 glucose augment treatment-induced increase sustained increase
EGF glucose augment treatment-induced increase transient increase
TGF-alpha glucose augment treatment-induced increase transient increase

S21-p - GSK3A (rat)
Modsite: SGRARtssFAEPGGG SwissProt Entrez-Gene
Orthologous residues
GSK3A (human): S21‑p, GSK3A (mouse): S21‑p, GSK3A (rat): S21‑p, GSK3A (cow): S21‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  INS-1 (pancreatic)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
glucose increase
IGF-1 glucose augment treatment-induced increase sustained increase
EGF glucose augment treatment-induced increase transient increase
TGF-alpha glucose augment treatment-induced increase transient increase